Allergan (AGN) to Acquire Tobira Therapeutics (TBRA) for $28.35/Share in Cash and up to $49.84 in CVRs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Tobira (TBRA) Large Shareholder Pentwater Buys, Not Sells Following Allergan Deal
September 22, 2016 5:02 PM EDTIn an interestingly development, large Tobira Therapeutics (NASDAQ: TBRA) shareholder Pentwater Capital did not cash out following the 733% surge in the stock after the acquisition announcement by Allergan (NYSE: AGN). Instead, the firm has added to its position.
The... More
Cantor Fitzgerald Downgrades Tobira Therapeutics (TBRA) to Hold Following Takeover
September 21, 2016 9:12 AM EDTCantor Fitzgerald downgraded Tobira Therapeutics (NASDAQ: TBRA) from Buy to Hold with a price target of $42.00 (from $19.00) after the company agreed to be acquired by Allergan.
For an analyst ratings summary and ratings history on Tobira Therapeutics... More
Allergan (AGN) is on A Major Buying Spree... And It's Just Getting Started
September 20, 2016 4:46 PM EDTAllergan (NYSE: AGN) is wasting little time spending the $29 billion in net cash proceeds it received from the generics sale to Teva. The company has announced four deals since the start of September, including two in the last 12 hours:
09/06 - Allergan plc (NYSE: AGN) agreed to acquire RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore... More
